Genovis announces a strategic partnership with Dutch CRO Single Cell Discoveries.
Redeye comments on Avensia’s preliminary sales figures for February 2026.
Agtira står inför ett skifte mot lönsam tillväxt efter förvärvet av Pepino.
Xplora completed a NOK150m private placement at NOK52 per share — a reasonable 6.
Enviro has signed a non-binding LOI regarding licensing of its pyrolysis technology in North America...
CapMan continues its strategic execution towards EUR 10bn in AUM by launching Infrastructure debt op...
Fluoguide announced that FG001 has been awarded FDA Fast Track designation, in a major validation of...
Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disord...
Redeye provides an initial comment on BioVica’s Q3 2025/2026 report.
Redeye comments on Scandinavian Chemotech announcing that its subsidiary Scandinavian Meditech has r...
Seafire enters 2026 with improving earnings momentum, supported by operational initiatives implement...
We hosted an investor event with Gofore management that focused on how AI is changing the IT service...
Redeye briefly comments on Isofol setting the final terms for the exercise of its TO1 warrants issue...
Redeye returns with an update following SciBase Holding’s Q4 report.
Xplora announced today it has agreed to key terms to acquire Emporia Mobile, the second-largest seni...
Xplora has acquired Emporia, the leading provider of senior mobile phones in the DACH region, enhanc...
Fortsatt momentum i den kapitallätta basaffären möter försvarstillväxt.
Investmentbolaget Creades har länge varit synonymt med tillväxt och historisk premievärdering.
Fastator redovisar kraftiga förluster för 2025 på -551 mkr efter nedskrivningar i fastigheter och in...
Redeye leaves a comment following Cinclus’ announcement that it has secured a structured growth-debt...
